港股異動 | 先健科技(1302.HK)漲4.87% IBS Angel鐵基可吸收支架系統成功完成美國首例植入
格隆匯3月29日丨先健科技(1302.HK)漲4.87%,報2.8港元,總市值129億港元。公司昨日發佈公吿,由先健科技控股子公司元心科技(深圳)有限公司自主研發的創新產品鐵基可吸收支架系統(“IBS Angel™”)於美國西艾利斯市威斯康辛州兒童醫院成功完成其於美國的首例植入。該產品通過美國FDA “Compassionate Use”(同情使用)批准,是先健科技鐵基可吸收材料平台下第二款在美國實現成功植入的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.